Abstract:Targeting proteins' enzymatic functions with small molecule inhibitors, as well as functions of receptor proteins with small-molecule agonists and antagonists, were the major forms of small-molecule drug development. These small-molecule modulators are based on a conventional occupancy-driven pharmacological approach. For proteome space traditionally considered undruggable by small-molecule modulators, such as enzymes with scaffolding functions, transcription factors, and proteins that lack well-defined binding pockets for small molecules, targeted protein degraders offer the opportunity to drug the proteome with an event-driven pharmacological approach. A degrader molecule, either PROTAC or molecular glue, brings the protein of interest (POI) and E3 ubiquitin ligase in close proximity and engages the ubiquitin-proteasome system (UPS), the cellular waste disposal system for the degradation of the POI. For the development of targeted protein degraders to meet therapeutic needs, several aspects will be considered, namely, the selective degradation of disease-causing proteins, the oral bioavailability of degraders beyond Lipinski's rule of five (bRo5) scope, demands of new E3 ubiquitin ligases and molecular glue degraders, and drug resistance of the new drug modality. This review will illustrate several under-discussed key considerations in targeted protein degradation drug discovery and development: 1) the contributing factors for the selectivity of PROTAC molecules and the design of PROTACs to selectively degrade synergistic pathological proteins; 2) assay development in combination with a multi-omics approach for the identification of new E3 ligases and their corresponding ligands, as well as molecular glue degraders; 3) a molecular design to improve the oral bioavailability of bRo5 PROTACs, and 4) drug resistance of degraders.

Targeting the Undruggables ---- the Power of Protein Degraders

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Recent advances in targeted protein degraders as potential therapeutic agents

Targeted protein degradation in drug development: Recent advances and future challenges

The new direction of drug development: Degradation of undruggable targets through targeting chimera technology

Emerging Targeted Protein Degradation Tools for Innovative Drug Discovery: from Classical PROTACs to the Novel and Beyond.

Targeted Protein Degradation: Principles, Strategies, and Applications

Targeted protein degradation: mechanisms, strategies and application

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Advancing targeted protein degradation for metabolic diseases therapy

Protein degradation technology: a strategic paradigm shift in drug discovery.

Major Advances in Emerging Degrader Technologies.

Key Considerations in Targeted Protein Degradation Drug Discovery and Development

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Targeted protein degradation: from mechanisms to clinic

Targeted protein degradation as a powerful research tool in basic biology and drug target discovery

Novel approaches to targeted protein degradation technologies in drug discovery

Emerging degrader technologies engaging lysosomal pathways

Advancing targeted protein degradation for cancer therapy